NASDAQ: DYAI - Dyadic International, Inc.

Rentabilität für sechs Monate: +8.85%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Dyadic International, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Dyadic International, Inc.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.

weitere details
The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2004-11-05
ISIN US26745T1016
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.dyadic.com
Цена ао 1.33
Preisänderung pro Tag: +1.65% (1.21)
Preisänderung pro Woche: -1.6% (1.25)
Preisänderung pro Monat: -12.14% (1.4)
Preisänderung über 3 Monate: -21.15% (1.56)
Preisänderung über sechs Monate: +8.85% (1.13)
Preisänderung pro Jahr: -26.79% (1.68)
Preisänderung über 3 Jahre: -50.8% (2.5)
Preisänderung über 5 Jahre: -70.78% (4.21)
Preisänderung seit Jahresbeginn: -35.43% (1.905)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 14.93 1
P/BV 21.13 1
P/E 0 0
EV/EBITDA -9.43 0
Gesamt: 3.25

Effizienz

Name Bedeutung Grad
ROA, % -64.01 0
ROE, % -139.16 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.9415 10
Gesamt: 8.6

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 118.46 10
Rentabilität Ebitda, % -47.24 0
Rentabilität EPS, % -41.64 0
Gesamt: 2
Weitere Details

Institutionen Volumen Aktie, %
Bandera Partners LLC 1566908 5.87
Chapin Davis, Inc. 826301 3.09
Vanguard Group Inc 803917 3.01
Northeast Financial Consultants Inc 250000 0.94
Blackrock Inc. 248614 0.93
Geode Capital Management, LLC 222696 0.83
Sage Mountain Advisors, LLC 106564 0.4
Northern Trust Corporation 77115 0.29
State Street Corporation 56550 0.21
Susquehanna International Group, LLP 48626 0.18



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Mark A. Emalfarb Founder, CEO, President & Director 874.37k 1956 (69 Jahre)
Ms. Ping Wang Rawson CPA, M.B.A. Chief Financial Officer 348.42k 1976 (49 Jahre)
Mr. Joseph P. Hazelton Chief Operating Officer 358.12k 1976 (49 Jahre)
Mr. Doug Pace B.A. Executive Vice President of Business Development N/A
Ms. Ana Gómez Rodriguez Secretary of the Board N/A

Adresse: United States, Jupiter. FL -, 1044 North U.S. Highway One - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.dyadic.com